TrialMenopause (New York, N.Y.)2020

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).

Nanette Santoro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.